Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSA-based versus concentration-based cisplatin dosing for OVHIPEC in advanced ovarian cancer
NL-OMON58647Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Intratumoral platinum concentration at end of perfusion. Started May 2022; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON58647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58647.